enalaprilat-anhydrous and Sepsis

enalaprilat-anhydrous has been researched along with Sepsis* in 3 studies

Trials

1 trial(s) available for enalaprilat-anhydrous and Sepsis

ArticleYear
Influence of angiotensin-converting enzyme inhibitor enalaprilat on endothelial-derived substances in the critically ill.
    Critical care medicine, 1998, Volume: 26, Issue:10

    To assess the effects of the angiotensin-converting enzyme inhibitor enalaprilat on endothelial cells in septic patients.. Prospective, randomized, placebo-controlled, blinded study.. Clinical investigation on a surgical intensive care unit of a university hospital.. Forty surgical septic patients (noncardiac/nonneurosurgical patients).. After inclusion in the study and after baseline data were obtained, either 0.25 mg/hr (enalaprilat group, n = 20) or saline solution as placebo (control group, n = 20) was continuously given and continued throughout the following 5 days.. Extensive hemodynamic monitoring was carried out in all patients. Plasma concentrations of endothelin-1, angiotensin II, soluble thrombomodulin, and soluble adhesion molecules (endothelial leukocyte adhesion molecule-1, intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and granule membrane protein-140) were measured from arterial blood samples. All measurements were carried out before the start of the infusion ("baseline" values) and daily during the following 5 days. All endothelial-derived substances (thrombomodulin, endothelin-1, and all soluble adhesion molecules) were similarly increased beyond normal in both group. Endothelin-1 increased only in the untreated control patients (from 6.9 +/- 0.7 to 14.3 +/- 1.4 mg/mL). Soluble thrombomodulin increased in the untreated control patients (from 58 +/- 9 to 79 +/- 14 ng/mL [p < .05]), but significantly decreased in the enalaprilat-treated patients. Soluble adhesion molecules increased in the untreated control group (endothelial leukocyte adhesion molecule from 92 +/- 14 to 192 +/- 29 ng/mL; intercellular adhesion molecule-1 from 480 +/- 110 to 850 +/- 119 ng/ mL) and returned almost to normal values in the enalaprilat patients. The survival rate did not differ significantly between the two groups. Control patients developed severe sepsis and septic shock more often than the enalaprilat-treated group.. The complex pathogenesis of endothelial function abnormalities in sepsis may offer a large number of pharmacologic interventions. Administration of the angiotensin-converting enzyme inhibitor enalaprilat resulted in a reduced release of soluble endothelial-derived substances into the circulating blood, which may indicate an improved endothelial function. The specific actions of enalaprilat on the endothelium have to be elucidated in further studies.

    Topics: Aged; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Cell Adhesion Molecules; Critical Illness; Double-Blind Method; Enalaprilat; Endothelin-1; Endothelium, Vascular; Female; Hemodynamics; Humans; Inflammation; Male; Middle Aged; Prospective Studies; Sepsis; Survival Analysis; Thrombomodulin

1998

Other Studies

2 other study(ies) available for enalaprilat-anhydrous and Sepsis

ArticleYear
What's new in Shock, June 2011?
    Shock (Augusta, Ga.), 2011, Volume: 35, Issue:6

    Topics: Animals; Burns; Disease Models, Animal; Enalaprilat; Humans; Hypoxia; Mitogen-Activated Protein Kinases; Nitric Oxide Synthase; Protoporphyrins; Sepsis; Shock

2011
Intravenous enalaprilat therapy for hypertension.
    DICP : the annals of pharmacotherapy, 1991, Volume: 25, Issue:1

    The angiotensin-converting enzyme inhibitor enalapril is available for intravenous administration in the form of enalaprilat. Intravenous enalaprilat is indicated for the management of hypertension when oral therapy is not feasible. However, there are no reports of intravenous enalaprilat therapy exceeding one week in duration. We report the case of a critically ill, 39-year-old woman who received intravenous enalaprilat for the management of hypertension for a period of 21 days. The patient's blood pressure and heart rate were controlled adequately on a regimen of enalaprilat 1.25 mg iv piggyback q6h without any apparent adverse effects.

    Topics: Adult; Drug Administration Schedule; Enalaprilat; Female; Humans; Hypertension; Infusions, Intravenous; Sepsis

1991